Online inquiry

IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ279MR)

This product GTTS-WQ279MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ279MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1197MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABP 980
GTTS-WQ4394MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-224818
GTTS-WQ9618MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ7520MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GC-1102
GTTS-WQ7974MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GX-17
GTTS-WQ14502MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA RYI-018
GTTS-WQ9709MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ12802MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-59R5
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW